LivaNova PLC (NASDAQ:LIVN)‘s stock had its “buy” rating reissued by research analysts at Berenberg Bank in a research note issued on Friday. They presently have a $70.00 price target on the stock. Berenberg Bank’s price target indicates a potential upside of 13.31% from the stock’s previous close.
Separately, BidaskClub downgraded LivaNova PLC from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $61.33.
LivaNova PLC (LIVN) opened at 61.78 on Friday. The firm has a 50-day moving average price of $61.64 and a 200-day moving average price of $55.08. The stock has a market cap of $3.02 billion, a P/E ratio of 110.32 and a beta of 0.62. LivaNova PLC has a 52 week low of $40.83 and a 52 week high of $64.95.
LivaNova PLC (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, August 9th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.19. LivaNova PLC had a return on equity of 9.08% and a net margin of 2.26%. The firm had revenue of $321.40 million for the quarter, compared to the consensus estimate of $315.75 million. The business’s quarterly revenue was up .1% compared to the same quarter last year. On average, equities research analysts predict that LivaNova PLC will post $3.16 EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/08/12/livanova-plc-nasdaqlivn-receives-buy-rating-from-berenberg-bank.html.
In related news, Director Sharon O’kane acquired 1,000 shares of the firm’s stock in a transaction dated Tuesday, May 23rd. The stock was bought at an average price of $58.58 per share, for a total transaction of $58,580.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $58,580. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 3,000 shares of company stock valued at $180,840 in the last 90 days. 0.28% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the stock. Comerica Bank boosted its position in shares of LivaNova PLC by 3.8% in the first quarter. Comerica Bank now owns 31,907 shares of the company’s stock valued at $1,672,000 after buying an additional 1,182 shares during the last quarter. Cambiar Investors LLC boosted its position in shares of LivaNova PLC by 16.9% in the first quarter. Cambiar Investors LLC now owns 7,841 shares of the company’s stock valued at $384,000 after buying an additional 1,136 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of LivaNova PLC by 5.1% in the first quarter. Bank of New York Mellon Corp now owns 374,488 shares of the company’s stock valued at $18,353,000 after buying an additional 18,042 shares during the last quarter. American Century Companies Inc. boosted its position in shares of LivaNova PLC by 232.5% in the first quarter. American Century Companies Inc. now owns 49,869 shares of the company’s stock valued at $2,444,000 after buying an additional 34,872 shares during the last quarter. Finally, Usca Ria LLC bought a new position in shares of LivaNova PLC during the first quarter valued at $415,000. Institutional investors own 73.41% of the company’s stock.
LivaNova PLC Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
What are top analysts saying about LivaNova PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for LivaNova PLC and related companies.